During the research phase of the collaboration, Xencor will provide CSL with the opportunity to utilize the technology broadly across its antibody candidate pipeline. Xencor has granted CSL several commercial licenses to move product candidates into development and ultimately commercialization which incorporate Xencor’s XmAb technology.
In addition to an upfront payment, CSL will pay Xencor development milestone payments and product royalties for each product commercialized that incorporates the Xencor technology.
Bassil Dahiyat, CEO of Xencor, said: “We are excited to collaborate with our CSL colleagues and enable their antibody products through the use of our XmAb technology.”